Preparing Compound Other Than Saccharide Containing A Tetracycline Nucleus (e.g., Naphacene, Etc.) Patents (Class 435/64)
  • Publication number: 20150125902
    Abstract: Provided are isolated polypeptides having glucoamylase activity, catalytic domains, and polynucleotides encoding the polypeptides, catalytic domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains.
    Type: Application
    Filed: August 24, 2012
    Publication date: May 7, 2015
    Applicant: Novozymes A/S
    Inventors: Tianqi Sun, Ming Li
  • Publication number: 20150125903
    Abstract: The present invention provides fungal xylanase and/or xylosidase enzymes suitable for use in saccharification reactions. The present invention provides xylanase and xylosidase enzymes suitable for use in saccharification reactions. The present application further provides genetically modified fungal organisms that produce xylanase(s) and/or xylosidase(s), as well as enzyme mixtures exhibiting enhanced hydrolysis of cellulosic material to fermentable sugars, enzyme mixtures produced by the genetically modified fungal organisms, and methods for producing fermentable sugars from cellulose using such enzyme mixtures. In some embodiments, the xylanase and xylosidase enzyme(s) are M. thermophila enzymes.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventors: Nicholas John Agard, David Elgart, Jie Yang, Goutami Banerjee, Jeanne Bonomo Benoit, Dipnath Baidyaroy
  • Publication number: 20150079627
    Abstract: The invention relates to processes of producing a fermentation product, comprising liquefying a starch containing material with an alpha-amylase; pre-saccharifying and/or saccharifying and fermenting using a fermentation organism in the presence of a carbohydrate source generating enzyme and a cellulolytic composition The invention also relates to methods of dewatering whole stillage.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 19, 2015
    Inventors: Thomas Rasmussen, Jeremy Saunders, James Croonenberghs, Zhengfang Kang, Joyce Craig, Michael John Akerman
  • Publication number: 20150079628
    Abstract: The present invention relates to a process for enzymatic hydrolysis of granular starch into a soluble starch hydrolysate at a temperature below the initial gelatinization temperature of said granular starch.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Anders Vikso-Nielsen, Carsten Andersen, Sven Pedersen, Carsten Hjort
  • Publication number: 20150056651
    Abstract: This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a chemical product, which includes polyketides and 3-hydroxypropionic acid.
    Type: Application
    Filed: April 7, 2014
    Publication date: February 26, 2015
    Inventors: Michael D. Lynch, Ryan T. Gill, Tanya E.W. Lipscomb
  • Patent number: 8916359
    Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: December 23, 2014
    Assignees: Novozymes A/S, Novozymes North America, Inc.
    Inventors: Sara Landvik, Marc Dominique Morant, Keiichi Ayabe, Guillermo Coward-Kelly
  • Publication number: 20140315243
    Abstract: The present invention relates to processes for producing fermentation products from starch-containing material, wherein an alpha-amylase, a thermostable protease, and optionally a carbohydrate-source generating enzyme and/or pullulanase, are present and/or added during liquefaction. The invention also relates to compositions suitable for use in a process of the invention.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 23, 2014
    Inventors: Randall Deinhammer, Joyce Craig, Tomoko Matsui, Shinobu Takagi, Suzanne Clark, John Matthews, Anne Glud Hjulmand, Chee-Leong Soong
  • Publication number: 20140206035
    Abstract: Provided are isolated polypeptides having glucoamylase activity, catalytic domains, and polynucleotides encoding the polypeptides, catalytic domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains.
    Type: Application
    Filed: August 24, 2012
    Publication date: July 24, 2014
    Inventors: Tianqi Sun, Ming Li
  • Patent number: 8697409
    Abstract: Disclosed are a ketoreductase mutant which can be used for an efficient production of daunorubicin derivatives, a DNA encoding the mutant, a transformant prepared by introducing the DNA thereinto to produce a daunorubicin derivative, and a process of producing a daunorubicin derivative using the transformant. The ketoreductase mutant has an amino acid sequence in which one amino acid residue or two or more amino acid residues selected from the group consisting of amino acids located at positions corresponding to the 42nd, 149th, 153rd, 270th, and 306th amino acids in the amino acid sequence of a ketoreductase (EvaE) from a chlororemomycin-producing bacterium (Amycolatopsis orientalis) are substituted with another amino acid residues.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: April 15, 2014
    Assignee: Meiji Seika Pharma Co., Ltd.
    Inventors: Fusuke Mazuka, Takayoshi Fukushima, Naomi Sumida, Koji Yanai
  • Publication number: 20130122541
    Abstract: This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a chemical product, which includes polyketides and 3-hydroxypropionic acid.
    Type: Application
    Filed: January 27, 2011
    Publication date: May 16, 2013
    Inventors: Michael D. Lynch, Ryan T. Gill, Tanya E.W. Lipscomb
  • Publication number: 20130116416
    Abstract: Disclosed are a ketoreductase mutant which can be used for an efficient production of daunorubicin derivatives, a DNA encoding the mutant, a transformant prepared by introducing the DNA thereinto to produce a daunorubicin derivative, and a process of producing a daunorubicin derivative using the transformant. The ketoreductase mutant has an amino acid sequence in which one amino acid residue or two or more amino acid residues selected from the group consisting of amino acids located at positions corresponding to the 42nd, 149th, 153rd, 270th, and 306th amino acids in the amino acid sequence of a ketoreductase (EvaE) from a chlororemomycin-producing bacterium (Amycolatopsis orientalis) are substituted with another amino acid residues.
    Type: Application
    Filed: May 21, 2010
    Publication date: May 9, 2013
    Applicant: MEIJI SEIKA PHARMA, CO., LTD.
    Inventors: Fusuke Mazuka, Takayoshi Fukushima, Naomi Sumida, Koji Yanai
  • Publication number: 20130095522
    Abstract: The present invention relates to processes for producing fermentation products from starch-containing material, wherein liquefied mash is saccharified or pre-saccharified using a thermostable carbohydrate-source generating enzyme before fermentation or SSF.
    Type: Application
    Filed: April 13, 2011
    Publication date: April 18, 2013
    Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/S
    Inventors: Randall Deinhammer, Guillermo Coward-Kelly, Ming Li, Junxin Duan, Zheng Liu, Shiro Fukuyama, Keiichi Ayabe
  • Patent number: 8399207
    Abstract: The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: March 19, 2013
    Assignee: Maine Medical Center
    Inventors: Lucy Liaw, Ah-Kau Ng
  • Patent number: 8383392
    Abstract: Disclosed is a transformant prepared by introducing a ketoreductase gene involved in the biosynthesis of L-epivancosamine into an actinobacterium originally capable of producing daunorubicin. Also disclosed is a process of efficiently producing a non-natural daunorubicin derivative using the transformant. The transformant is capable of efficiently producing a non-natural daunorubicin derivative such as epidaunorubicin.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: February 26, 2013
    Assignee: Meiji Seika Pharma Co., Ltd.
    Inventors: Naomi Sumida, Manabu Watanabe, Koji Yanai
  • Publication number: 20130017571
    Abstract: A truncated pullulanase variant of a parent pullulanase belonging to family GH57 comprising an X47 domain and the use thereof.
    Type: Application
    Filed: December 22, 2010
    Publication date: January 17, 2013
    Applicant: NOVOZYMES A/S
    Inventors: Martin Borchert, Morten Gjermansen, Suzanne Clark, Bernard Henrissat, Maria B. Silow, Peter F. Hallin
  • Patent number: 8329422
    Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CELLSPOTTERĀ® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: December 11, 2012
    Assignee: Veridex LLC
    Inventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W. M. M. Terstappen, Shawn Mark O'Hara, Steven Gross
  • Publication number: 20120276585
    Abstract: The present invention relates to a method for producing a hydrolysate of from lignocellulose-containing material, comprising pre-treatment with low temperature, hydrolysis and fermentation, wherein hydrolysis is performed by contacting the lignocellulose-containing material with an enzyme composition comprising at least 10% xylanase enzyme protein w/w%.
    Type: Application
    Filed: December 21, 2010
    Publication date: November 1, 2012
    Applicants: COFCO CORPORATION, NOVOZYMES A/S
    Inventors: Haiyu Ren, Dongmin Li, Yun Wang, Chuanji Fang, Hong Zhi Huang
  • Patent number: 8252599
    Abstract: Sample processing units useful for mixing and purifying materials, such as fluidic materials are provided. A sample processing unit typically includes a container configured to contain a sample comprising magnetically responsive particles, and one or more magnets that are in substantially fixed positions relative to the container. A sample processing unit also generally includes a conveyance mechanism configured to convey the container to and from a position that is within magnetic communication with the magnet, e.g., such that magnetically responsive particles with captured analytes can be retained within the container when other materials are added to and/or removed from the container. Further, a sample processing unit also typically includes a rotational mechanism that is configured to rotate the container, e.g., to effect mixing of sample materials disposed within the container. Related carrier mechanisms, sample processing stations, systems, and methods are also provided.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: August 28, 2012
    Assignee: Ibis Biosciences, Inc.
    Inventors: Steven A. Hofstadler, Jared J. Drader, Jose R. Gutierrez, Paul J. Gleason, Rex O. Bare, Robert D. Miller, Jeffrey C. Smith
  • Publication number: 20120214196
    Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: November 30, 2010
    Publication date: August 23, 2012
    Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/S
    Inventors: Sara Landvik, Marc Dominique Morant, Keiichi Ayabe, Guillermo Coward-Kelly
  • Publication number: 20120214197
    Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: November 30, 2010
    Publication date: August 23, 2012
    Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/S
    Inventors: Sara Landvik, Marc Dominique Morant, Keiichi Ayabe, Guillermo Coward-Kelly
  • Patent number: 8236928
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: August 7, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
  • Publication number: 20100291622
    Abstract: The present invention provides compounds which exhibit an inhibitory effect on undecaprenyl diphosphate synthase of microbes and thereby they are expected to be used clinically as pharmaceutical agents for infectious diseases caused by bacteria. The process comprises culturing a microbe belonging to Penicillium and having ability of producing an FKI-3368 substance in or on a nutrient medium to accumulate the FKI-3368 substance in the nutrient medium and collecting the FKI-3368 substance from the culture.
    Type: Application
    Filed: September 12, 2008
    Publication date: November 18, 2010
    Applicant: SCHOOL JURIDICAL PERSON KITASATO INSTITUTE
    Inventors: Hiroshi Tomoda, Junji Inokoshi, Rokuro Masuma, Satoshi Omura
  • Patent number: 7820386
    Abstract: A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation state of the CpG sequence in at least one target gene within the genomic DNA of the test specimen, wherein the target genes is consisted of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the presence or absence of the methylation state in the target gene; wherein method for detecting methylation state is methylation-specific PCR (MSP), quantitative methylation-specific PCR (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: October 26, 2010
    Assignee: National Defense Medical Center
    Inventor: Hung-Cheng Lai
  • Publication number: 20100124583
    Abstract: Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.
    Type: Application
    Filed: April 3, 2009
    Publication date: May 20, 2010
    Applicant: XYLECO, INC.
    Inventor: Marshall Medoff
  • Patent number: 7666609
    Abstract: This invention relates to monoclonal antibodies that recognize an antigen specific to melanocytic lesions. These antibodies are useful in methods of isolating melanoma cells and diagnosing melanocytic lesions. These antibodies are also useful for immunotherapy against melanoma.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: February 23, 2010
    Assignee: Shanghai CP GuoJian Pharmaceutical Co. Ltd.
    Inventors: Yajun Guo, Jing Ma
  • Publication number: 20100035847
    Abstract: The invention relates to genetically engineered cells, and to proteins and genes useful in the production of tetracycline compounds, to methods of producing tetracycline compounds, and to tetracyclines thereby produced. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway.
    Type: Application
    Filed: August 6, 2009
    Publication date: February 11, 2010
    Inventors: Hrvoje Petkovic, Peter Raspor, Urska Lesnik
  • Patent number: 7605144
    Abstract: This invention provides novel compounds selected from the group consisting of a 1,5-substituted pyrimidine derivative or analog and substituted furano-pyrimidone analogs. The compounds are useful to treat or prevent diseases such as cancer.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: October 20, 2009
    Assignee: Celmed Oncology (USA), Inc.
    Inventors: H. Michael Shepard, Ming Fai Chan, Michael P. Groziak
  • Patent number: 6750040
    Abstract: Cell-free systems which effect the production of polyketides employing modular polyketide synthases are described. Libraries of new and/or known polyketides may also be produced in cell-free systems employing aromatic PKS, modular PKS or both.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: June 15, 2004
    Assignees: Board of Trustees of the Leland Stanford Junior University, Brown University Research Foundation
    Inventors: Chaitan Khosla, Rembert Pieper, Guanglin Luo, David E. Cane
  • Publication number: 20030138879
    Abstract: The invention pertains to isolated phosphopantetheinyl transferases, such as the E. coli acyl carrier protein synthase, which transfer a phosphopantetheinyl group onto a substrate. The enzyme can be purified from a natural source, produced recombinantly, or synthetically. Accordingly, the invention provides compositions and kits including phosphopantetheinyl transferases and host cells expressing phosphopantetheinyl transferases. The invention also provides nucleic acids encoding phosphopantetheinyl transferases and vectors comprising such nucleic acids. The invention further provides methods for phosphopantetheinylating a substrate in vitro or in vivo and methods for producing antibiotics in vitro or in vivo.
    Type: Application
    Filed: September 30, 2002
    Publication date: July 24, 2003
    Applicant: President and Fellows of Harvard College
    Inventors: Ralph H. Lambalot, Amy M. Gehring, Ralph Reid, Christopher T. Walsh
  • Publication number: 20020031522
    Abstract: Overexpression of a CRAF1 (CD40 receptor-associated factor 1) gene truncated by 323 to about 414 amino acids at the amino inhibits CD40-mediated cell activation, and is used to treat conditions characterized by an unwanted level of CD40-mediated intracellular signaling.
    Type: Application
    Filed: March 10, 1997
    Publication date: March 14, 2002
    Inventors: DAVID BALTIMORE, GENHONG CHENG, ZHENG-SHENG YE, SETH LEDERMAN, AILEEN CLEARY
  • Publication number: 20010051356
    Abstract: The stereochemical centers of a polyketide can be changed by replacement of ketosynthase domains in the polyketide synthase (PKS) enzyme that produces the polyketide. The specificity of the AT domains of a PKS is determined by a hypervariable region that can be replaced or altered to change the specificity of the AT domain from a naturally occurring extender unit to another naturally or non-naturally occurring extender unit. Non-naturally occurring extender units, including methylmalonyl N-acetyl cysteamine thioester can be incorporated into polyketides in recombinant host cells or in cell-free systems to make polyketides.
    Type: Application
    Filed: December 12, 2000
    Publication date: December 13, 2001
    Inventors: Chaitan Khosla, Janice Lau, Nicola L. Pohl
  • Patent number: 6288272
    Abstract: The present invention relates to a continuous process for preparing optically pure (S)-3,4-dihydroxybutyric acid derivatives expressed by the following Formula 1 and more particularly, to the continuous process which enables preparing optically pure (S)-3,4-dihydroxybutyric acid derivatives economically in large quantities, by: (a) Preparing &agr;-(1,4) linked oligosaccharide having adequate sugar distribution by reacting amylopectin which is easily available from natural product with enzyme under a specific condition; and (b) Performing oxidatioin by running basic anion exchange resin with an oxidant to give (S)-3,4-dihydroxybutyric acid-anion exchange resin complex, dissociating the (S)-3,4-dihydroxybutyric acid from anion exchange resin complex and esterification sequentially under a specific condition.  wherein Represents linear or branched alkyl group with 1˜5 carbon atoms.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: September 11, 2001
    Assignee: Samsung Fine Chemicals Co., Ltd.
    Inventors: Kyoung Rok Roh, Jongpil Chun, Yik-haeng Cho, Young Mi Park, Hosung Yu, Dae Il Hwang
  • Patent number: 6261766
    Abstract: This invention relates to the detection of prostate-specific antigen (PSA) in female breast tumor extract as a prognostic or predictive indicator for breast carcinoma. The presence of prostate-specific antigen in breast tumours is associated with earlier disease stage, younger women and better survival. PSA is associated with tumors which have estrogen and/or progersterone receptors.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: July 17, 2001
    Assignee: Nordion International, Inc.
    Inventor: Eleftherios Diamandis
  • Patent number: 6232443
    Abstract: Nuclear matrix proteins (NMP) are useful markers in diagnosing and monitoring the stage of malignancy of a cell, and in treating cell proliferative disorders associated with the NMP.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: May 15, 2001
    Assignee: University of Pittsburgh
    Inventor: Robert H. Getzenberg
  • Patent number: 6080555
    Abstract: Cell-free systems which effect the production of polyketides employing modular polyketide synthases are described. Libraries of new and/or known polyketides may also be produced in cell-free systems employing aromatic PKS, modular PKS or both.
    Type: Grant
    Filed: July 5, 1996
    Date of Patent: June 27, 2000
    Assignees: Stanford University, Brown University
    Inventors: Chaitan Khosla, Rembert Pieper, Guanglin Luo, David E. Cane
  • Patent number: 5989903
    Abstract: Recombinant S. aureofaciens cells are provided. These cells comprise:(a) at least one CTC 11 gene; and (b) optionally(i) a CTC 09 gene;(ii) a CTC 03 gene; or(iii)a combination thereof;wherein:the CTC 11 gene is chromosomal, extra-chromosomal, or chromosomal and extra-chromosomal;the CTC 09 gene, CTC 03 gene, or a combination thereof is chromosomal, extra-chromosomal, or a combination thereof;expression of the CTC 11 gene is enhanced over that of a wild-type S. aureofaciens cell; andoptionally, the CTC 09 gene, the CTC 03 gene, or both of the CTC 09 gene and the CTC 03 gene are inactivated.The present invention also contemplates vector pLP21329 and vectors for allelic replacement in a S. aureofaciens host cell. The vectors comprise:(a) a functional E.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 23, 1999
    Assignee: American Cyanamid Company
    Inventor: Michael J. Ryan
  • Patent number: 5965429
    Abstract: Recombinant S. aureofaciens cells are provided. These cells comprise: (a) at least one CTC 11 gene; and (b) optionally(i) a CTC 09 gene;(ii) a CTC 03 gene; or(iii) a combination thereof;wherein:the CTC 11 gene is chromosomal, extra-chromosomal, or chromosomal and extra-chromosomal;the CTC 09 gene, CTC 03 gene, or a combination thereof is chromosomal, extra-chromosomal, or a combination thereof; expression of the CTC 11 gene is enhanced over that of a wild-type S. aureofaciens cell; andoptionally, the CTC 09 gene, the CTC 03 gene, or both of the CTC 09 gene and the CTC 03 gene are inactivated.The present invention also contemplates vector pLP21329 and vectors for allelic replacement in a S. aureofaciens host cell. The vectors comprise:(a) a functional E.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: October 12, 1999
    Assignee: American Cyanamid Company
    Inventor: Michael J. Ryan
  • Patent number: 5925531
    Abstract: The present invention provides immortalized human bone marrow endothelial cells which are useful for the study of tumor metastasis. In particular, the human bone marrow endothelial cell lines provided by the invention provide an in vitro model system for screening compounds for the ability to reduce, prevent, or inhibit the metastasis of cancer cells to bone tissue.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: July 20, 1999
    Assignee: The Regents of the University of Michigan
    Inventor: Kenneth J. Pienta
  • Patent number: 5840494
    Abstract: This invention provides a method of determining the stage of prostate cancer in a human subject using a sample of peripheral blood from a human subject. The invention uses reverse transcriptase-PCR to detect the mRNA encoding prostate specific antigen (PSA) in circulating cells expressing PSA. The invention further uses digoxigenin enhancement of the resultant cDNA signal. The method has an overall sensitivity capable of detecting one PSA expressing cell per 100,000 cells. The method produced no false positives and had a superior detection selectivity for patients with nonlocalized prostate cancer.
    Type: Grant
    Filed: April 18, 1997
    Date of Patent: November 24, 1998
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Aaron E. Katz, Ralph Buttyan, Anthony Raffo, Carl A. Olsson
  • Patent number: 5217877
    Abstract: The present invention relates to a novel .alpha.-glucosidase inhibitor, pradimicin Q, having the following formula ##STR1## and its pharmaceutically acceptable base salts.
    Type: Grant
    Filed: December 11, 1991
    Date of Patent: June 8, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yosuke Sawada, Tomokazu Ueki, Takashi Tsuno, Toshikazu Oki
  • Patent number: 5183758
    Abstract: An antibiotic complex is produced by the microorganism, Actinomadura brunnea NRRL 15216, ATCC 39216. A novel antibiotic 7-chloro-8-methoxy-2'-N-methyltetracycline, isolated from the antibiotic complex, is active against gram-positive and gram-negative aerobes.
    Type: Grant
    Filed: May 23, 1990
    Date of Patent: February 2, 1993
    Assignee: Schering Corporation
    Inventor: Ann C. Horan
  • Patent number: 5100921
    Abstract: New angucyclinones with a therapeutic action can be prepared with the aid of a strain of the genus Streptomyces.
    Type: Grant
    Filed: April 25, 1989
    Date of Patent: March 31, 1992
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Susanne Grabley, Joachim Wink, Carlo Giani, Gerhard Seibert, Wolfgang Raether, Susanne Dobreff, Axel Zeeck
  • Patent number: 5066585
    Abstract: A new species of Micromonospora, in particular Micromonospora spartanea ATCC 53803, is described. The species produces antifungal compounds spartanamicins A and B. Methods for the production, isolation and characterization of the compounds are described. The compounds contain deoxy-L-fucose, as well as another hexose and an amino sugar.
    Type: Grant
    Filed: November 23, 1990
    Date of Patent: November 19, 1991
    Assignee: Board of Trustees Operating Michigan State University
    Inventors: Alan R. Putnam, Saroj K. Mishra, Muraleedharan G. Nair
  • Patent number: 4977084
    Abstract: A new species of Micromonospora, in particular Micromonospora spartanea ATCC 53803, is described. The species produces new antifungal compounds spartanamicins A and B. Methods for the production, isolation and characterization of the compounds are described. The new compounds contain spartanose, which is a new hexose sugar, as well as another hexose and an amino sugar.
    Type: Grant
    Filed: February 16, 1989
    Date of Patent: December 11, 1990
    Assignee: Board of Trustees operating Michigan State University
    Inventors: Alan R. Putnam, Saroj K. Mishra, Muraleedharan G. Nair
  • Patent number: 4752605
    Abstract: The antibiotic 7273 complex is elaborated by the microorganism, Dactylosporangium vescum ATCC 39499. The novel 7-chloro-4a-hydroxy-8-methoxytetracycline isolated from antibiotic 7273 complex is active against gram-positive and gram-negative aerobes.
    Type: Grant
    Filed: August 9, 1985
    Date of Patent: June 21, 1988
    Assignee: Schering Corporation
    Inventors: Mahesh G. Patel, Ann C. Horan, Joseph A. Marquez, George H. Miller, Richard W. Vaughan
  • Patent number: 4385122
    Abstract: A novel anthracycline antibiotic complex, fragilomycin complex, is produced by the cultivation of a fermentation broth containing Streptosporangium fragile Shearer sp. nov. ATCC 31519 microorganisms in an aqueous nutrient medium under submerged aerobic conditions. The fragilomycin complex and its major bioactive component, fragilomycin A, exhibit antibiotic activity.
    Type: Grant
    Filed: August 21, 1981
    Date of Patent: May 24, 1983
    Assignee: SmithKline Beckman Corporation
    Inventors: Claude H. Nash, III, Marcia C. Shearer, Kenneth M. Snader, Joseph R. Valenta, David Cooper